Senti BiosciencesSNTI
SNTI
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
34% more capital invested
Capital invested by funds: $2.41M [Q3] → $3.23M (+$824K) [Q4]
14% more funds holding
Funds holding: 14 [Q3] → 16 (+2) [Q4]
3.21% less ownership
Funds ownership: 23.27% [Q3] → 20.06% (-3.21%) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Research analyst outlook
We haven’t received any recent analyst ratings for SNTI.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47.6 million from private investment in public equity (PIPE) financing – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the fourth quarter of 2024 and provided a summary of recent pipeline and corporate highlights.
Neutral
GlobeNewsWire
2 weeks ago
Senti Bio Appoints Feng Hsiung to Board of Directors
– Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) – – Company also announced inducement grants under Nasdaq Listing Rule 5635(c)(4) –
Neutral
GlobeNewsWire
1 month ago
Senti Bio Strengthens Leadership Team with Strategic Hires
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESS Newswire / February 7, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESS Newswire / February 5, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESS Newswire / February 4, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc
NEW YORK, NY / ACCESS Newswire / February 3, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
1 month ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Neutral
Accesswire
2 months ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Senti Biosciences Inc.
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own Senti Biosciences Inc ("SNTI" or the "Company") (NASDAQ:SNTI) Stock purchased prior to June 1, 2022. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as Dynamics Special Purpose Co., and whether the Board of SNTI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.
Charts implemented using Lightweight Charts™